Opinion

Video

Emerging Treatments for Patients with NMIBC

A panelist discusses how emerging investigational agents for NMIBC show promise through diverse mechanisms, including oncolytic viruses (CG0070), immune checkpoint inhibitors (durvalumab, sasanlimab), targeted drug delivery systems (TAR-200), mitomycin-containing gels (UGN-102/103), immunotherapies (TARA-002), gene therapies (EG-70), and FGFR inhibitors (erdafitinib), representing a robust pipeline of potential treatment options.

  • Please give an overview and your overall impressions about selected investigational agents to treat patients with NMIBC.
    • Cretostimogene grenadenorepvec (CG0070)
    • Durvalumab
    • Tar-200
    • UGN-102 and UGN 103
    • Sasanlimab
    • TARA-002
Related Videos
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
Related Content
© 2025 MJH Life Sciences

All rights reserved.